Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Last trade$40.44
Day change-$1.81 (-4.28%)
Day range$39.53 – $42.85
Volume123,339
Market cap$121M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$121.43M
Price / earnings
—
Price / book
1.83×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.67×
Profitability
Earnings per share
-$23.36
Return on assets
-73.03%
Return on equity
-101.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.12×
Current ratio
4.83×
Quick ratio
4.83×
Cash ratio
4.69×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51.21M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SPRB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$697K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$697K
Selling, general and administrative
$5.85M
$4.35M
$4.41M
$7M
$3.22M
$3.12M
$3.66M
$3.31M
Research and development
$18.13M
$12.16M
$7.58M
$4.1M
$5.01M
-$430K
$10.84M
$21.46M
Total operating expenses
$23.98M
$16.51M
$11.99M
$11.1M
$8.23M
$2.69M
$14.49M
$24.77M
Operating income
-$23.98M
-$16.51M
-$11.99M
-$11.1M
-$8.23M
-$2.69M
-$14.49M
-$24.07M
Interest expense
-$1.2M
-$1.1M
-$674K
-$6K
-$19K
-$29K
-$36K
-$56K
Income before taxes
-$24.01M
-$16.23M
-$12.27M
-$14.65M
-$8.21M
-$2.07M
-$14.04M
-$23.56M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$24.01M
-$16.23M
-$12.27M
-$14.65M
-$8.21M
-$2.07M
-$14.04M
-$23.56M
Net income attributable to common shareholders
-$24.01M
-$16.23M
-$12.27M
-$14.65M
-$8.21M
-$2.07M
-$14.04M
-$23.56M
EBITDA
-$23.24M
-$15.88M
-$11.74M
-$11.1M
-$8.23M
-$2.69M
-$14.49M
-$24.07M
Basic earnings per share
-$8.51
-$6.68
-$8.94
-$11.04
-$14.58
-$3.50
-$23.95
-$42.59
Diluted earnings per share
-$8.51
-$6.68
-$8.94
-$11.04
-$14.58
-$3.50
-$23.95
-$42.59
Recent news
Company coverage with links to the original publishers.
U.S. stock futures rose on Tuesday following Monday's decline, with major indices edging higher. Markets are focused on U.S.-Iran negotiations in Islamabad and Kevin Warsh's Fed Chair confirmation hearing. Key stocks in focus include Apple (CEO transition), UnitedHealth (earnings expected), 3M (earnings expected), Amazon (Anthropic partnership expansion), and Spruce Biosciences (stock offering announcement).
The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.